Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,236.92 +4,019.73 (+6.79%) CMC Crypto 200
1,363.40 +86.42 (+6.77%)
Rocket Pharmaceuticals, Inc. (RCKT)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 22.77 |
| Open | 23.63 |
| Bid | 23.37 x 100 |
| Ask | 23.49 x 300 |
| Day's range | 23.31 - 23.99 |
| 52-week range | 14.89 - 32.53 |
| Volume | |
| Avg. volume | 737,758 |
| Market cap | 2.13B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.92 |
| Earnings date | 03 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.33 |
ZacksRocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
Rocket Pharmaceuticals (RCKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Insider MonkeyShould You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
ZacksEMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
© 2024 Yahoo. All rights reserved.